Observational studyJCO precision oncology2025
Observational study in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Molecular and clinicopathological characteristics ofHistology and histopathology · 2026Review
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review.The Laryngoscope · 2026Article
- Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.Endocrine-related cancer · 2026Article
- Diagnostic Utility of a Cost-Effective Four-Gene Next Generation Sequencing Panel for Predicting Papillary Thyroid Carcinoma in Indeterminate Thyroid Cytology: A Multicenter Study in China.Cancer medicine · 2026Article
- Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications.Discover oncology · 2026Article
- Tumor microenvironment-guided targeted and immunotherapy in anaplastic thyroid cancer: a literature review from preclinical models to clinical translation.Translational cancer research · 2026Review
- Clinicopathological and sonographic characterization of NTRK-fusion papillary thyroid carcinoma based on preoperative molecular testing: a comparative study with BRAFFrontiers in oncology · 2026Article
- The actual and future role of molecular tests in thyroid pathology.Virchows Archiv : an international journal of pathology · 2026Review
- Targeted therapy in thyroid cancer: molecular alterations and clinical management.Frontiers in endocrinology · 2026Review
- Redifferentiation Effect of Larotrectinib forJournal of the Endocrine Society · 2025Article
- Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy.Journal of clinical medicine · 2025Review
- Multimodal spectrum of approach in poorly differentiated thyroid carcinoma (an updated analysis).Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
- Erratum issued
Authors and funding
22 authors.
Funding
Abstract
purposeNeurotrophic tropomyosin receptor kinase (
methodsThis is an observational retrospective study conducted at a single high-volume cancer center in the United States. Data were retrospectively collected from medical records.
resultsWe included 65 patients (37 adult, 28 pediatric) with an
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.